Your browser doesn't support javascript.
loading
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Hochhaus, A; Baccarani, M; Silver, R T; Schiffer, C; Apperley, J F; Cervantes, F; Clark, R E; Cortes, J E; Deininger, M W; Guilhot, F; Hjorth-Hansen, H; Hughes, T P; Janssen, J J W M; Kantarjian, H M; Kim, D W; Larson, R A; Lipton, J H; Mahon, F X; Mayer, J; Nicolini, F; Niederwieser, D; Pane, F; Radich, J P; Rea, D; Richter, J; Rosti, G; Rousselot, P; Saglio, G; Saußele, S; Soverini, S; Steegmann, J L; Turkina, A; Zaritskey, A; Hehlmann, R.
Afiliação
  • Hochhaus A; Klinik für Innere Medizin II, Universitätsklinikum, Jena, Germany. andreas.hochhaus@med.uni-jena.de.
  • Baccarani M; Department of Hematology/Oncology, Policlinico S. Orsola-Malpighi, University of Bologna, Bologna, Italy.
  • Silver RT; Weill Cornell Medical College, New York, NY, USA.
  • Schiffer C; Karmanos Cancer Center, Detroit, MI, USA.
  • Apperley JF; Hammersmith Hospital, Imperial College, London, UK.
  • Cervantes F; Hospital Clinic IDIBAPS, Barcelona, Spain.
  • Clark RE; Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
  • Cortes JE; Georgia Cancer Center, Augusta University, Augusta, GA, USA.
  • Deininger MW; Huntsman Cancer Center Salt Lake City, Salt Lake City, UT, USA.
  • Guilhot F; Centre Hospitalier Universitaire de Poitiers, Poitiers, France.
  • Hjorth-Hansen H; Norwegian University of Science and Technology, Trondheim, Norway.
  • Hughes TP; South Australian Health and Medical Research Institute, Adelaide, SA, Australia.
  • Janssen JJWM; Amsterdam University Medical Center, VUMC, Amsterdam, The Netherlands.
  • Kantarjian HM; MD Anderson Cancer Center, Houston, TX, USA.
  • Kim DW; St. Mary´s Hematology Hospital, The Catholic University, Seoul, Korea.
  • Larson RA; University of Chicago, Chicago, IL, USA.
  • Lipton JH; University of Toronto, Toronto, Canada.
  • Mahon FX; Institut Bergonie, Université de Bordeaux, Bordeaux, France.
  • Mayer J; Department of Internal Medicine, Masaryk University Hospital, Brno, Czech Republic.
  • Nicolini F; Centre Léon Bérard, Lyon, France.
  • Niederwieser D; Universitätsklinikum, Leipzig, Germany.
  • Pane F; Department Clinical Medicine and Surgery, University Federico Secondo, Naples, Italy.
  • Radich JP; Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Rea D; Hôpital St. Louis, Paris, France.
  • Richter J; University of Lund, Lund, Sweden.
  • Rosti G; Department of Hematology/Oncology, Policlinico S. Orsola-Malpighi, University of Bologna, Bologna, Italy.
  • Rousselot P; Centre Hospitalier de Versailles, University of Versailles Saint-Quentin-en-Yvelines, Versailles, France.
  • Saglio G; University of Turin, Turin, Italy.
  • Saußele S; III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany.
  • Soverini S; Department of Hematology/Oncology, Policlinico S. Orsola-Malpighi, University of Bologna, Bologna, Italy.
  • Steegmann JL; Hospital de la Princesa, Madrid, Spain.
  • Turkina A; National Research Center for Hematology, Moscow, Russian Federation.
  • Zaritskey A; Almazov National Research Centre, St. Petersburg, Russian Federation.
  • Hehlmann R; III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany. hehlmann.eln@gmail.com.
Leukemia ; 34(4): 966-984, 2020 04.
Article em En | MEDLINE | ID: mdl-32127639
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Proteínas de Fusão bcr-abl / Inibidores de Proteínas Quinases / Mesilato de Imatinib / Antineoplásicos Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Leukemia Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Proteínas de Fusão bcr-abl / Inibidores de Proteínas Quinases / Mesilato de Imatinib / Antineoplásicos Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Leukemia Ano de publicação: 2020 Tipo de documento: Article